Aurinia Pharmaceuticals (AUPH) Posts Wider Q2 Loss

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of ($0.26), $0.12 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $29 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS
• Citi sees this stock as primary lithium demand beneficiary, upgrades to Buy